VISTIDE TREATMENT FOR RELAPSING CMV RETINITIS IN PATIENTS WITH AIDS

接受治疗艾滋病患者复发性巨细胞病毒视网膜炎

• 批准号: 6122108
• 负责人: BRUCE A BARRON
• 金额: $ 1.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-19 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122108
• 关键词: AIDS; antiviral agents; clinical research; cytomegalovirus; eye disorder chemotherapy; human subject; human therapy evaluation; opportunistic infections; relapse /recurrence; retinitis

The Vistide treatment for Relapsing Cytomegalovirus Retinitis in patients with AIDS is a research study designed to: 1) make intravenous Vistide more broadly available to patients with CMV retinitis who cannot tolerate, or have progressed despite treatment with Ganciclovir and/or foscarnet, and 2) gather additional information about the safety and effectiveness of intravenous Vistide in the treatment of relapsing CMV retinitis in patients with AIDS. Patients with AIDS are at high risk for reactivation of CMV. CMV infection may be asymptomatic. However, CMV may progress and cause severe and potentially disabling damage to the lungs, gastrointestinal tract and the retina of the eye.

Vistide治疗AIDS患者复发性巨细胞病毒视网膜炎是一项研究，旨在：1）使静脉Vistide更广泛地用于不能耐受或尽管使用更昔洛韦和/或膦甲酸治疗仍进展的CMV视网膜炎患者，2）收集关于静脉Vistide治疗AIDS患者复发性CMV视网膜炎的安全性和有效性的其他信息。 艾滋病患者CMV再激活的风险很高。CMV感染可能无症状。 然而，CMV可能会进展并对肺部，胃肠道和眼睛视网膜造成严重和潜在的致残性损害。